Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  777 results for ""NATALIZUMAB""

Your Filters

Subject : disease progression
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/pharmacology

  • Source: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Aug; Vol. 11 (8), pp. 2008-2015. Date of Electronic Publication: 2024 Jul 05.Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.

  • Authors : Scherer L; Department of Neurology, Nancy University Hospital, 54035, Nancy, France.; Soudant M

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/therapeutic use ; Disease Progression* ; Immunologic Factors*/Immunologic Factors*/Immunologic Factors*/administration & dosage

  • Source: Journal of neurology [J Neurol] 2024 May; Vol. 271 (5), pp. 2216-2224. Date of Electronic Publication: 2024 Feb 29.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.

  • Authors : Ladeira F; Neurology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, R. da Junqueira 126, 1349-019, Lisbon, Portugal. Electronic address: .; Braz L

Subjects: Disease Progression*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*diagnosis

  • Source: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2019 Sep; Vol. 184, pp. 105390. Date of Electronic Publication: 2019 Jun 16.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Subjects: Disease Progression* ; Outcome Assessment, Health Care* ; Severity of Illness Index*

  • Source: The Lancet. Neurology [Lancet Neurol] 2018 May; Vol. 17 (5), pp. 405-415. Date of Electronic Publication: 2018 Mar 12.Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.

Subjects: COGNITIVE ability; NATALIZUMAB; MILD cognitive impairment

  • Source: Acta Neurologica Scandinavica. Jan2018, Vol. 137 Issue 1, p117-124. 8p.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Subjects: MULTIPLE sclerosis treatment; NATALIZUMAB; BIOMARKERS

  • Source: Acta Neurologica Scandinavica. Mar2014, Vol. 129 Issue 3, pe12-e15. 4p.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

  • Authors : Sastre-Garriga J; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain .; Tur C

Subjects: Disease Progression*; Brain/Brain/Brain/*pathology ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*pharmacology

  • Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2015 May; Vol. 21 (6), pp. 749-56. Date of Electronic Publication: 2014 Nov 12.Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

  • Authors : Vidal-Jordana A; Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Tintoré M

Subjects: Disease Progression*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*drug therapy

  • Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2015 May; Vol. 21 (6), pp. 780-5. Date of Electronic Publication: 2014 Nov 12.Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Natalizumab in Multiple Sclerosis: A Single Centre Real-World Study.

Subjects: NATALIZUMAB; MULTIPLE sclerosis; PATIENT safety

  • Source: Journal of Multiple Sclerosis Research; Aug2024, Vol. 4 Issue 2, p47-51, 5p

Record details

Read More Add to Saved list
×
Academic Journal

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

  • Authors : Novakova L; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Axelsson M

Subjects: Disease Progression*; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*cerebrospinal fluid ; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*drug therapy

  • Source: Journal of neurochemistry [J Neurochem] 2017 Apr; Vol. 141 (2), pp. 296-304. Date of Electronic Publication: 2016 Nov 29.Publisher: Wiley on behalf of the International Society for Neurochemistry Country of Publication: England NLM ID: 2985190R Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
  • 1-10 of  777 results for ""NATALIZUMAB""